Jefferies lowered the firm’s price target on HealthEquity (HQY) to $108 from $120 and keeps a Buy rating on the shares. Pre-released Q4 operational metrics show “strong” HSA account growth of 6.9% year-over-year and asset growth of 13.6% year-over-year, notes the analyst, who believe that the stock is “a great defensive option” for investors who want to maintain exposure to healthcare and/or tech but without the AI risk to its business model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity: Above-Consensus HSA Growth and Cautious Valuation Support Buy Rating
- HealthEquity price target lowered to $110 from $118 at Barclays
- HealthEquity backs FY26 EPS view $3.87-$3.95, consensus $3.95
- HealthEquity backs FY27 revenue view $1.38B-$1.41B, consensus $1.41B
- HealthEquity reports HSAs as of January 31 10.6M, up 7%